Company Profile
Xeris Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- XERS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.36 USD (-9.25%)
Close
Last updated: August 6, 2026
1.04B USD
Market cap
Why the stock is moving
Following the latest company update, “Xeris Biopharma Reports Second Quarter 2026 Financial Results”, XERS closed down 9.25% at $7.36 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Specialty Biopharmaceutical Portfolio
Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.
Endocrine Products
Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome. Gvoke is a ready-to-use liquid glucagon for severe hypoglycemia. Keveyis is an oral therapy for primary periodic paralysis. Together, the portfolio gives Xeris a multi-product commercial platform serving specialist prescribers and patients with chronic or episodic endocrine disorders.
Future catalysts
Xeris’s catalysts are Recorlev, Gvoke, and the company’s endocrinology portfolio. Investors will watch whether the commercial base keeps broadening beyond a single product story.
Recent news
- 01
Xeris Biopharma Reports Second Quarter 2026 Financial Results
Source: Xeris Pharmaceuticals
- 02
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
Source: Xeris Pharmaceuticals
- 03
Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Source: Xeris Pharmaceuticals
- 04
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Source: Xeris Pharmaceuticals
- 05
Xeris Announces Updates to Its Board of Directors
Source: Xeris Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Xeris Pharmaceuticals (XERS)?
Xeris Pharmaceuticals (XERS) most recently closed at 7.36 USD, a -9.25% move versus the previous session.
What is the market cap of Xeris Pharmaceuticals (XERS)?
Xeris Pharmaceuticals currently has a market capitalization of 1.04B USD on BioPharmSignal.
What does Xeris Pharmaceuticals do?
Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability. Endocrine Products Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome. Gvoke is a ready-to-use...
On which exchange is XERS stock listed?
Xeris Pharmaceuticals (XERS) is associated with NASDAQ, United States, Biopharma.
What is Specialty?
Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.
Which conditions is Xeris Pharmaceuticals targeting with Specialty?
Xeris Pharmaceuticals is associated with neurology based on its company overview and current catalyst commentary.
How does Xeris Pharmaceuticals describe recent progress with Specialty?
Xeris’s catalysts are Recorlev, Gvoke, and the company’s endocrinology portfolio. Investors will watch whether the commercial base keeps broadening beyond a single product story.
What is Biopharmaceutical?
Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.